news
FDA approves new indications for Gilead’s Harvoni
13 November 2015 | By Victoria White
The FDA has approved Harvoni for expanded use in patients with genotype 4, 5 and 6 chronic HCV infection and in patients co-infected with HIV...
List view / Grid view
Hepatitis
news
Johnson & Johnson to acquire Novira Therapeutics
5 November 2015 | By Victoria White
The acquisition includes Novira's portfolio of novel antivirals, including its lead candidate, NVR 3-778...
news
NICE issues positive guidance for Viekirax + Exviera in HCV
19 October 2015 | By Victoria White
Viekirax and Exviera are the first treatments for chronic HCV to combine three direct-acting antiviral agents to target the infection at multiple steps in the viral lifecycle...
news
NICE recommends Daklinza for chronic HCV
16 October 2015 | By Victoria White
NICE has recommended Daklinza for the treatment of patients with chronic hepatitis C virus genotypes 1, 3 and 4...
news
FDA grants priority review for HCV treatment Daklinza sNDAs
6 October 2015 | By Victoria White
The applications are for the treatment of patients with chronic HCV coinfected with HIV-1, patients with advanced cirrhosis, and for patients with post-liver transplant recurrence of HCV...
news
HCV therapy Elbasvir/grazoprevir shows sustained virologic response
6 October 2015 | By Victoria White
Elbasvir/grazoprevir showed sustained virologic response in patients with chronic hepatitis C virus with advanced chronic kidney disease...
news
AbbVie’s Viekirax approved as HCV treatment in Japan
28 September 2015 | By Victoria White
The approval provides a new interferon and ribavirin-free treatment option for patients with most common type of hepatitis in Japan...
news
Study reports high sustained viral response with Viekirax + Exviera in GT1 HCV
11 September 2015 | By Victoria White
Interim results from the independent AMBER study demonstrated a 98% SVR12 rate in patients who completed a 12- or 24-week treatment regimen...
news
EC approves label update for BMS’ Daklinza
10 September 2015 | By Victoria White
The update allows the use of Daklinza in combination with sofosbuvir for 12 weeks in patients without cirrhosis in all 28 Member States of the European Union...
news
NICE recommends three new treatments for hepatitis C in draft guidance
29 July 2015 | By Victoria White
The UK National Institute for Health and Care Excellence has published draft guidance recommending three different treatment options for hepatitis C...
news
PHE publishes annual report on hepatitis C
28 July 2015 | By Victoria White
The latest figures from Public Health England show hospital admissions from hepatitis C-related end-stage liver disease and liver cancer continue to rise...
news
FDA approves Daklinza for the treatment of HCV genotype 3
27 July 2015 | By Victoria White
Daklinza has been approved by the US FDA, marking the first time patients with chronic HCV genotype 3 have a 12-week, once-daily, all-oral treatment option...
news
AbbVie announces new positive Phase 3b results in genotype 1b chronic HCV patients with compensated liver cirrhosis
24 June 2015 | By Victoria White
TURQUOISE-III study results demonstrate 100% sustained virologic response in genotype 1b chronic HCV patients with compensated liver cirrhosis...
news
Telbivudine prevents passage of HBV during pregnancy
2 June 2015 | By Victoria White
The antiviral drug telbivudine prevents perinatal transmission of hepatitis B virus (HBV), according to a new study...
news
Top-line results announced for Phase 2 study of GS-4774 in patients with chronic hepatitis B
28 May 2015 | By Victoria White
Top line results have been announced from the GS-4774 Phase 2 study in patients with HBV on long term viral suppression with an oral antiviral treatment...
